Big Pharma' Turns To Biologics For Growth To 2010: Financial And Strategic Segmentation Of The 'Big Pharma' Sector By Drug Technology - Biologics Market Research

Big Pharma' Turns To Biologics For Growth To 2010: Financial And Strategic Segmentation Of The 'Big Pharma' Sector By Drug Technology

Published Date: May 2006
Published By: Datamonitor
Page Count: 139
Order Code: R313-14357
Price: $7,600.00 Online Download
$15,200.00 Global Site License
Note: If you don't see the format or license type you require, please contact a customer service representative for assistance.

DESCRIPTION

Introduction
'Big Pharma' (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins and monoclonal antibodies): by 2010, annual sales of biologics will have increased by $26bn, compared to a $13bn increase for small molecules.
Scope
Global sales forecasts for all Big Pharma products, split by company, therapy area and technology type, spanning the period 2001-10
Introduction to the 'technology lifecycle' concept and assignment of each of the four drug classes to distinct positions along the lifecycle
Evaluation of the competitive forces that impact the drug types, including generic exposure, access to new technology suppliers and pricing leverage
Strategic assessment of Roche's relationship with Genentech, and Novartis' contrasting approach of pursuing growth in the small molecule arena
Highlights
Within the Big Pharma peer set, the revenue growth rate to 2010 forecast for biologics is a robust CAGR of 13.0%, outstripping the near-static CAGR of 0.9% predicted for small molecules. The small molecule growth rate is depressed by continued exposure to intense generic competition.
Big Pharma has assumed a strong position within the antibody market, a major attraction of this product type being the total absence of generic risk. In contrast, bio-similars are an emerging threat for members of the therapeutic protein class.
Roche is the leading Big Pharma player within the biologics market. It holds an extremely strong position in the antibody market thanks to its 1990 merger with Genentech. As a result, Roche is forecast to record the highest sales growth rate to 2010 within the peer set, equal to an increase in annual company sales of $14bn.
Reasons to Purchase
Understand, in dollar terms, the changing nature of product technology within 'Big Pharma' using sales forecasts through to 2010
Assess the competitive forces driving significantly stronger growth for antibodies in comparison to small molecules and therapeutic proteins
Be prepared for the end-of-decade acceleration in vaccine sales and scan the horizon for future technology waves, including nucleic acid therapeutics